Home » News » Clinical Intelligence » CureFAKtor drug inhibits pancreatic tumor growth

CureFAKtor drug inhibits pancreatic tumor growth

Friday, April 6, 2012

CureFAKtor Pharmaceuticals, a privately-held biopharmaceutical company, has reported data demonstrating analogs of novel focal adhesion kinase (FAK) inhibitor CFAK-C4 disrupted FAK-vascular endothelial growth factor receptor 3 (FAK-VEGFR3) interaction and inhibited pancreatic tumor growth.

Data showed that oral small molecule FAK inhibitor C4 analogs disrupt FAK-VEGFR3 interaction and dramatically inhibit pancreatic tumor growth at low concentrations as single agents, as well as in combination with gemcitabine, demonstrating synergistic effect. In vivo, 30-day treatment with low doses of the four analogs led to massive reduction in tumor growth when treated as single agents (60%) and in combination with gemcitabine (80%) (P<0.05). The C4 analogs displayed enhanced potency, minimum toxicity and high specificity for the target site.

A previous CureFAKtor study pinpointed the site of interaction of VEGFR-3 and FAK to create the small molecule drug capable of disrupting signaling and causing death of many types of cancer cells.

CureFAKtor is planning a phase I clinical study of CFAK-C4 in combination with gemcitabine chemotherapy in 2012, which received Orphan Drug Designation by the FDA.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!